A new trading day began on Tuesday, with Seres Therapeutics Inc (NASDAQ: MCRB) stock price down -4.74% from the previous day of trading, before settling in for the closing price of $0.77. MCRB’s price has ranged from $0.54 to $1.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 477.44% over the past five years. Meanwhile, its annual earnings per share averaged 86.52%. With a float of $124.81 million, this company’s outstanding shares have now reached $170.20 million.
Let’s look at the performance matrix of the company that is accounted for 233 employees. In terms of profitability, gross margin is -10887.5%, operating margin of -221404.69%, and the pretax margin is -258259.37%.
Seres Therapeutics Inc (MCRB) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Seres Therapeutics Inc is 26.90%, while institutional ownership is 23.57%. The most recent insider transaction that took place on Nov 18 ’24, was worth 475. In this transaction Chief Legal Officer and EVP of this company sold 878 shares at a rate of $0.54, taking the stock ownership to the 135,192 shares. Before that another transaction happened on Nov 18 ’24, when Company’s insider sold 977 for $0.54, making the entire transaction worth $528. This insider now owns 32,415 shares in total.
Seres Therapeutics Inc (MCRB) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 86.52% per share during the next fiscal year.
Seres Therapeutics Inc (NASDAQ: MCRB) Trading Performance Indicators
Here are Seres Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 1.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2080.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Seres Therapeutics Inc (MCRB)
Seres Therapeutics Inc (NASDAQ: MCRB) saw its 5-day average volume 3.28 million, a positive change from its year-to-date volume of 2.04 million. As of the previous 9 days, the stock’s Stochastic %D was 18.62%. Additionally, its Average True Range was 0.07.
During the past 100 days, Seres Therapeutics Inc’s (MCRB) raw stochastic average was set at 24.43%, which indicates a significant increase from 8.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.72% in the past 14 days, which was lower than the 93.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8178, while its 200-day Moving Average is $0.8851. Nevertheless, the first resistance level for the watch stands at $0.7600 in the near term. At $0.7891, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8088. If the price goes on to break the first support level at $0.7112, it is likely to go to the next support level at $0.6915. Assuming the price breaks the second support level, the third support level stands at $0.6624.
Seres Therapeutics Inc (NASDAQ: MCRB) Key Stats
With a market capitalization of 124.81 million, the company has a total of 170,738K Shares Outstanding. Currently, annual sales are 126,330 K while annual income is -113,720 K. The company’s previous quarter sales were 0 K while its latest quarter income was 88,780 K.
